G
Gordon H. Guyatt
Researcher at McMaster University
Publications - 1749
Citations - 262329
Gordon H. Guyatt is an academic researcher from McMaster University. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 231, co-authored 1620 publications receiving 228631 citations. Previous affiliations of Gordon H. Guyatt include Memorial Sloan Kettering Cancer Center & Cayetano Heredia University.
Papers
More filters
Journal ArticleDOI
Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.
Antonio L. Dans,Leonila F. Dans,Mary Ann Lansang,Maria Asuncion A. Silvestre,Gordon H. Guyatt +4 more
TL;DR: In this article, the authors conducted a sub-group analysis to support claims that the vaccine is probably safe among children aged 9 years or more and found that the more likely explanation for the higher risk in younger children is more frequent seronegativity, rather than age itself.
Journal ArticleDOI
Methodologic problems in clinical trials in heart failure.
TL;DR: Trials designed to establish the effectiveness of pharmacologic therapy in chronic heart failure illustrate methodologic problems associated with intervention trials in chronic disease.
Journal ArticleDOI
Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis.
Francois Lamontagne,Matthias Briel,Mark Duffett,Alison Fox-Robichaud,Deborah J. Cook,Gordon H. Guyatt,Olivier Lesur,Maureen O. Meade +7 more
TL;DR: This work assesses literature reviews of therapeutic interventions for sepsis that include animal experiments for explicit appraisals of the risk of bias and clinical relevance and proposes a framework to enhance these features in future reviews of preclinical research.
Journal ArticleDOI
Troponin T monitoring to detect myocardial injury after noncardiac surgery: a cost-consequence analysis.
Giovanna Lurati Buse,Giovanna Lurati Buse,Braden J. Manns,Andre Lamy,Gordon H. Guyatt,Carisi Anne Polanczyk,Matthew T. V. Chan,Chew Yin Wang,Juan Carlos Villar,Alben Sigamani,Daniel I. Sessler,Otavio Berwanger,Bruce M Biccard,Rupert M Pearse,Gerard Urrútia,R. Wojciech Szczeklik,Ignacio Garutti,Sadeesh Srinathan,Germán Málaga,Valsa Abraham,Clara K Chow,Michael J. Jacka,Maria Tiboni,Gareth L. Ackland,Danielle MacNeil,Robert J. Sapsford,Martin Leuwer,Yannick Le Manach,Philip J. Devereaux +28 more
TL;DR: Based on the estimated incremental cost per health gain, implementation of postoperative troponin T monitoring seems appealing, particularly in patients at high risk for MINS, especially in patients aged 45 years or older undergoing inpatient noncardiac surgery.
Journal ArticleDOI
What is a disease? Perspectives of the public, health professionals and legislators
TL;DR: There is large disagreement among the public, health professionals and legislators regarding the classification of states of being as diseases and whether their management should be publicly funded.